US8829208B2 - Process for the preparation of darunavir and darunavir intermediates - Google Patents
Process for the preparation of darunavir and darunavir intermediates Download PDFInfo
- Publication number
- US8829208B2 US8829208B2 US13/519,297 US201113519297A US8829208B2 US 8829208 B2 US8829208 B2 US 8829208B2 US 201113519297 A US201113519297 A US 201113519297A US 8829208 B2 US8829208 B2 US 8829208B2
- Authority
- US
- United States
- Prior art keywords
- formula
- compound
- furan
- hexahydrofuro
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 *C(=O)O[C@H]1CO[C@H]2OCC[C@@H]12.C.CC(C)CCC[C@@H](O)[C@H](CC1=CC=CC=C1)N=[N+]=[N-].CC(C)CN.CC(C)CN(C[C@@H](O)[C@@H](CC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@@H](N)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.I.O=[N+]([O-])C1=CC=C(ClOOS)C=C1.[N-]=[N+]=N[C@@H](CC1=CC=CC=C1)[C@H]1CO1 Chemical compound *C(=O)O[C@H]1CO[C@H]2OCC[C@@H]12.C.CC(C)CCC[C@@H](O)[C@H](CC1=CC=CC=C1)N=[N+]=[N-].CC(C)CN.CC(C)CN(C[C@@H](O)[C@@H](CC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@@H](N)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.I.O=[N+]([O-])C1=CC=C(ClOOS)C=C1.[N-]=[N+]=N[C@@H](CC1=CC=CC=C1)[C@H]1CO1 0.000 description 9
- PWROURNJPHEKRZ-UHFFFAOYSA-N CCCC(C=O)C(O)CC Chemical compound CCCC(C=O)C(O)CC PWROURNJPHEKRZ-UHFFFAOYSA-N 0.000 description 3
- IHSLQSPANQVGPP-WDEREUQCSA-N CC[C@@H](O)[C@@H](N)CC1=CC=CC=C1 Chemical compound CC[C@@H](O)[C@@H](N)CC1=CC=CC=C1 IHSLQSPANQVGPP-WDEREUQCSA-N 0.000 description 2
- NGJGWOMVKGHZBB-KUIMJXCQSA-M C.CC(C)CN.CC(C)CNC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1COC2OCC[C@H]21.CC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1COC2OCC[C@H]21.[V].[V]I Chemical compound C.CC(C)CN.CC(C)CNC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1COC2OCC[C@H]21.CC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1COC2OCC[C@H]21.[V].[V]I NGJGWOMVKGHZBB-KUIMJXCQSA-M 0.000 description 1
- OKWYXWIACZDGCL-JSXJTQDKSA-N C1CN[C@H](C2=NN=NN2)C1.CC12CCC(C(=O)O[C@H]3CN[C@H](C(=O)O)C3)(OC1=O)C2(C)C.CC1=CC(C)=C(NC(=O)[C@@H]2CCCN2)C(C)=C1.CC1=CC=CC(NC(=O)[C@@H]2CCCN2)=N1.CCCCCCCCCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.CCOC(=O)C(NC(=O)[C@@H]1CCCN1)[C@@H](O)C(=O)OCC.CC[C@@H](NC(=O)[C@@H]1CCCN1)C1=CC=CC=C1.C[C@H](NC(=O)C1CCCC1)[C@H](O)C1=CC=CC=C1.C[C@H]1CN[C@H](C(=O)O)C1.N=NC(=O)[C@@H]1CCCN1.O=C(C[C@@H](NC(=O)[C@H]1CCCN1)C1=CC=CC=C1)OCC1=CC=CC=C1.O=C(NC(C1=CC=CC=C1)[C@@H](O)C1=CC=CC=C1)[C@@H]1CCCN1 Chemical compound C1CN[C@H](C2=NN=NN2)C1.CC12CCC(C(=O)O[C@H]3CN[C@H](C(=O)O)C3)(OC1=O)C2(C)C.CC1=CC(C)=C(NC(=O)[C@@H]2CCCN2)C(C)=C1.CC1=CC=CC(NC(=O)[C@@H]2CCCN2)=N1.CCCCCCCCCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.CCOC(=O)C(NC(=O)[C@@H]1CCCN1)[C@@H](O)C(=O)OCC.CC[C@@H](NC(=O)[C@@H]1CCCN1)C1=CC=CC=C1.C[C@H](NC(=O)C1CCCC1)[C@H](O)C1=CC=CC=C1.C[C@H]1CN[C@H](C(=O)O)C1.N=NC(=O)[C@@H]1CCCN1.O=C(C[C@@H](NC(=O)[C@H]1CCCN1)C1=CC=CC=C1)OCC1=CC=CC=C1.O=C(NC(C1=CC=CC=C1)[C@@H](O)C1=CC=CC=C1)[C@@H]1CCCN1 OKWYXWIACZDGCL-JSXJTQDKSA-N 0.000 description 1
- AXDSFIMXCAQEKU-GKCBHUKXSA-N C1CN[C@H](C2=NN=NN2)C1.CC12CCC(C(=O)O[C@H]3CN[C@H](C(=O)O)C3)(OC1=O)C2(C)C.CC1=CC(C)=C(NC(=O)[C@@H]2CCCN2)C(C)=C1.CC1=CC=CC(NC(=O)[C@@H]2CCCN2)=N1.CCCCCCCCCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.CC[C@@H](NC(=O)[C@@H]1CCCN1)C1=CC=CC=C1.C[C@H](NC(=O)C1CCCC1)[C@H](O)C1=CC=CC=C1.C[C@H]1CN[C@H](C(=O)O)C1.NC(=O)[C@@H]1CCCN1.O=C(C[C@@H](NC(=O)[C@H]1CCCN1)C1=CC=CC=C1)OCC1=CC=CC=C1.O=C(N[C@@H](C1=CC=CC=C1)C(O)C1=CC=CC=C1)[C@@H]1CCCN1 Chemical compound C1CN[C@H](C2=NN=NN2)C1.CC12CCC(C(=O)O[C@H]3CN[C@H](C(=O)O)C3)(OC1=O)C2(C)C.CC1=CC(C)=C(NC(=O)[C@@H]2CCCN2)C(C)=C1.CC1=CC=CC(NC(=O)[C@@H]2CCCN2)=N1.CCCCCCCCCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.CC[C@@H](NC(=O)[C@@H]1CCCN1)C1=CC=CC=C1.C[C@H](NC(=O)C1CCCC1)[C@H](O)C1=CC=CC=C1.C[C@H]1CN[C@H](C(=O)O)C1.NC(=O)[C@@H]1CCCN1.O=C(C[C@@H](NC(=O)[C@H]1CCCN1)C1=CC=CC=C1)OCC1=CC=CC=C1.O=C(N[C@@H](C1=CC=CC=C1)C(O)C1=CC=CC=C1)[C@@H]1CCCN1 AXDSFIMXCAQEKU-GKCBHUKXSA-N 0.000 description 1
- HCIWTOAYXAPOQX-WUUZAEBNSA-N C1CN[C@H](CN2CCCC2)C1.CCN1C=C(CO[C@H]2CN[C@H](C(=O)O)C2)N=N1.CN1C(=O)[C@H](CC2=CC=CC=C2)N[C@@H]1C(C)(C)C.COC(=O)CCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]1CCCN1)CC1=CC=CC=C1.C[C@@H]1C[C@H](N2CCCC2)CN1.O=C(O)C(F)(F)F.O=CO[C@@H]1CC[C@@H](C(=O)O)N1.O=P(O)(O)[C@H]1CCCN1.O=S(=O)(NC[C@@H]1CCCN1)C(F)(F)F.P=S.[H][C@@]12CCCC[C@]1([H])N[C@H](C(=O)O)C2 Chemical compound C1CN[C@H](CN2CCCC2)C1.CCN1C=C(CO[C@H]2CN[C@H](C(=O)O)C2)N=N1.CN1C(=O)[C@H](CC2=CC=CC=C2)N[C@@H]1C(C)(C)C.COC(=O)CCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]1CCCN1)CC1=CC=CC=C1.C[C@@H]1C[C@H](N2CCCC2)CN1.O=C(O)C(F)(F)F.O=CO[C@@H]1CC[C@@H](C(=O)O)N1.O=P(O)(O)[C@H]1CCCN1.O=S(=O)(NC[C@@H]1CCCN1)C(F)(F)F.P=S.[H][C@@]12CCCC[C@]1([H])N[C@H](C(=O)O)C2 HCIWTOAYXAPOQX-WUUZAEBNSA-N 0.000 description 1
- OFUAVQJNSOEAJT-YABUZCHASA-N C1CN[C@H](CN2CCCC2)C1.CCN1C=C(CO[C@H]2CN[C@H](C(=O)O)C2)N=N1.CN1C(=O)[C@H](CC2=CC=CC=C2)N[C@@H]1C(C)(C)C.COC(=O)CCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.O=C(O)C(F)(F)F.O=C(O)[C@@H]1C[C@H](N2CCCC2)CN1.O=CO[C@@H]1CC[C@@H](C(=O)O)N1.O=P(O)(O)[C@H]1CCCN1.P=S.[H][C@@]12CCCC[C@]1([H])N[C@H](C(=O)O)C2 Chemical compound C1CN[C@H](CN2CCCC2)C1.CCN1C=C(CO[C@H]2CN[C@H](C(=O)O)C2)N=N1.CN1C(=O)[C@H](CC2=CC=CC=C2)N[C@@H]1C(C)(C)C.COC(=O)CCC(=O)O[C@H]1CN[C@H](C(=O)O)C1.O=C(O)C(F)(F)F.O=C(O)[C@@H]1C[C@H](N2CCCC2)CN1.O=CO[C@@H]1CC[C@@H](C(=O)O)N1.O=P(O)(O)[C@H]1CCCN1.P=S.[H][C@@]12CCCC[C@]1([H])N[C@H](C(=O)O)C2 OFUAVQJNSOEAJT-YABUZCHASA-N 0.000 description 1
- ZCJJSCUFEXXCQB-XQTICPGVSA-N CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C([N+](=O)[O-])C=C1.[HH] Chemical compound CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C([N+](=O)[O-])C=C1.[HH] ZCJJSCUFEXXCQB-XQTICPGVSA-N 0.000 description 1
- NRDNAYIRPLPDCD-MKVUQSLOSA-O CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@@H](N)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.[H+] Chemical compound CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@@H](N)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.[H+] NRDNAYIRPLPDCD-MKVUQSLOSA-O 0.000 description 1
- SAYZHXZCYJHYDN-ULCDRCKISA-N CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C([N+](=O)[O-])C=C1.CC(C)CNC[C@@H](O)[C@@H](C)CC1=CC=CC=C1.O=[N+]([O-])C1=CC=C(ClOOS)C=C1 Chemical compound CC(C)CN(C[C@@H](O)[C@@H](C)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C([N+](=O)[O-])C=C1.CC(C)CNC[C@@H](O)[C@@H](C)CC1=CC=CC=C1.O=[N+]([O-])C1=CC=C(ClOOS)C=C1 SAYZHXZCYJHYDN-ULCDRCKISA-N 0.000 description 1
- GHLIMFFCKFURED-RVJIPUPZSA-N CC(C)CN(C[C@@H](O)[C@@H](N)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCO[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1.I.O=C(O[C@H]1CO[C@H]2OCC[C@@H]12)ON1C(=O)CCC1=O Chemical compound CC(C)CN(C[C@@H](O)[C@@H](N)CC1=CC=CC=C1)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCO[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1.I.O=C(O[C@H]1CO[C@H]2OCC[C@@H]12)ON1C(=O)CCC1=O GHLIMFFCKFURED-RVJIPUPZSA-N 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1 Chemical compound CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- WRXJFWRVSDNWKY-CGUNJFSISA-N CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCO[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CNC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1COC2OCC[C@H]21.I.NC1=CC=C(ClOOS)C=C1.[V] Chemical compound CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCO[C@@H]12)S(=O)(=O)C1=CC=C(N)C=C1.CC(C)CNC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1COC2OCC[C@H]21.I.NC1=CC=C(ClOOS)C=C1.[V] WRXJFWRVSDNWKY-CGUNJFSISA-N 0.000 description 1
- JPRHMBHVTFHTTQ-ZEJWJDBWSA-N CC(C)CN.CC(C)CNC[C@@H](O)[C@@H](C)CC1=CC=CC=C1.C[C@@H](CC1=CC=CC=C1)[C@H]1CO1 Chemical compound CC(C)CN.CC(C)CNC[C@@H](O)[C@@H](C)CC1=CC=CC=C1.C[C@@H](CC1=CC=CC=C1)[C@H]1CO1 JPRHMBHVTFHTTQ-ZEJWJDBWSA-N 0.000 description 1
- MPNCFAAXPSBGDJ-UHZRXMQZSA-N CC(C)CNC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12 Chemical compound CC(C)CNC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12 MPNCFAAXPSBGDJ-UHZRXMQZSA-N 0.000 description 1
- RHLCCKLEZRVDMT-UHFFFAOYSA-N CCCC(N=O)C(O)CC Chemical compound CCCC(N=O)C(O)CC RHLCCKLEZRVDMT-UHFFFAOYSA-N 0.000 description 1
- QISMSMLVSHHALY-ZOFXXKQRSA-N CC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12 Chemical compound CC[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12 QISMSMLVSHHALY-ZOFXXKQRSA-N 0.000 description 1
- YXWOYBQZWSLSMU-VHSXEESVSA-N N[C@@H](CC1=CC=CC=C1)[C@H](O)CCl Chemical compound N[C@@H](CC1=CC=CC=C1)[C@H](O)CCl YXWOYBQZWSLSMU-VHSXEESVSA-N 0.000 description 1
- LZUNKLCSVVTYDY-XHNCKOQMSA-N O=C(O[C@H]1CO[C@H]2OCC[C@@H]12)N1C=CN=C1 Chemical compound O=C(O[C@H]1CO[C@H]2OCC[C@@H]12)N1C=CN=C1 LZUNKLCSVVTYDY-XHNCKOQMSA-N 0.000 description 1
- VCFNCYVHQSHFRH-MHYGZLNHSA-N O=C(O[C@H]1CO[C@H]2OCC[C@@H]12)ON1C(=O)CCC1=O Chemical compound O=C(O[C@H]1CO[C@H]2OCC[C@@H]12)ON1C(=O)CCC1=O VCFNCYVHQSHFRH-MHYGZLNHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Definitions
- the present invention relates to a process for the preparation of darunavir, a nonpeptide protease inhibitor (PI), useful for the treatment of HIV/AIDS in patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens.
- the present invention further relates to processes for the preparation of darunavir intermediates, and to certain novel intermediates obtained by such processes.
- HIV-1 protease inhibitors have proven to be effective additions to existing antiretroviral regimens.
- MDR multidrug resistance
- Darunavir is a next-generation nonpeptide PI that exhibits potent antiviral activity with low toxicity in vitro and in vivo. The agent retains activity against resistant strains and has low liability for the development of resistance.
- Darunavir was approved by the FDA under the name PREZISTATM, and is administered in combination with a low-dose of ritonavir and other active anti-HIV agents.
- Azidoepoxide is a hazard compound, which is not commercially available. Because of this, different approaches were proposed to substitute this compound with more readily available analogs. For example PCT patent applications WO 2005/063770, WO 2008/132154 disclose:
- (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol is a precursor of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivates and is a key intermediate for the preparation of darunavir.
- a common feature of some prior art processes for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol is the use, at different stages of the process, of protecting groups that are acid-sensitive, and therefore removed under acidic conditions. Such acidic conditions are a prerequisite of the cyclization process forming the furanol ring.
- protecting groups used in the synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol include benzyl ether protecting groups, alkyl ether protective groups and silyl protecting groups.
- a major disadvantage of the synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol according to the available protocols is that the desired compound is initially obtained in the form of a diastereomer racemic mixture of hexahydrofuro[2,3-b]furan-3-ols.
- Optical resolution methods are generally inefficient and expensive.
- Examples include (i) optical resolution carried out by enzymes, this reaction is inefficient since only one of the resulting enantiomers is used for the production of an intended substance, while the other enantiomer is discarded; (ii) using an optically active form as a raw material, this option is non-economical as optically active compounds are expensive; (iii) conversion of the racemic mixture into the corresponding acetate followed by enzymatic hydrolysis; and (iv) oxidizing the racemic mixture followed by a reducing step.
- Another clear disadvantage of the available procedures is the simultaneous deprotection (intermolecular reaction) and ring closure processes (intramolecular reaction) which take place under acidic conditions and result in reduced product yields.
- the present invention provides a process for the preparation of darunavir, a compound of formula (I) (chemically designated [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl) propyl]-carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl ester).
- the applicants of the present invention have discovered a process by which the compound of formula (I) may be prepared on a manufacturing scale from the compound
- X is a leaving group.
- leaving groups include a halogen (e.g., Cl, Br, I) or a sulfonate leaving group (e.g., MsO and TsO).
- X is Cl.
- the compound of formula (I) can be synthesized in only three distinct stages instead of five as previously described. According to some embodiments, the first and the second stages are performed together in a single step. According to other embodiments, the entire process can be performed as “one-pot” synthesis. Each possibility represents a separate embodiment of the present invention.
- the improved process reduces the amount of waste products formed. Furthermore, product may be obtained in a higher yield, e.g., approximately 80-90%.
- the process of the present invention involves the synthesis of compound of formula (I) starting from the compound of formula (II) comprising the following steps:
- the tetrahydrofuranol derivative (III) is prepared and coupled with the compound (II) in a single step.
- the present invention also relates to the stereoisomeric forms of the compounds employed in the process according to the invention including starting materials and compounds subsequently prepared from compounds which are prepared in accordance with certain embodiments of the present invention.
- the compound of formula (II) can be used as a free base or, according to some embodiments, in the form of salt. According to certain embodiments the salt is a hydrochloride salt.
- the compound of formula (II) may be prepared by several ways available in the literature.
- the compound of formula (II) is coupled with a hexahydrofuro[2,3-b]furan-3-yl derivative (III) to obtain compound of formula (IV).
- R is halogen (e.g., Cl, Br, I), imidazolyl, benzotriazolyl, oxysuccinimidyl, oxybenzotriazolyl, 4-nitrophenoxy, 4-methoxyphenoxy, 2-nitrophenoxy, pentafluorophenoxy or other analogous groups typically used for formation of active esters.
- halogen e.g., Cl, Br, I
- imidazolyl benzotriazolyl
- oxysuccinimidyl oxybenzotriazolyl
- 4-nitrophenoxy 4-methoxyphenoxy
- 2-nitrophenoxy pentafluorophenoxy or other analogous groups typically used for formation of active esters.
- the compound of formula (III) can be prepared from (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol in a conventional manner, for example as described in WO 2005/000249.
- the (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol is suitably activated with a coupling agent to generate a hexahydrofuro[2,3-b]furan-3-yl derivative (III) which is then coupled with the compound of formula (II) to obtain the compound (IV).
- Non-limiting examples of coupling agents that may be used in the preparation of compound (III) are carbonates such as bis-(4-nitrophenyl)carbonate, and disuccinimidyl carbonate (DSC), carbonyl diimidazole (CDI), chloroformates, such as p-nitrophenylchloroformate, phosgene or triphosgene.
- carbonates such as bis-(4-nitrophenyl)carbonate, and disuccinimidyl carbonate (DSC), carbonyl diimidazole (CDI), chloroformates, such as p-nitrophenylchloroformate, phosgene or triphosgene.
- step (ii) is carried out by reacting the compound of formula (IV) with isobutylamine to form compound (V), with isobutylamine as solvent or in a suitable solvent including, but not limited to an alcohol (e.g., ethanol), an ester (e.g., ethyl acetate), an ether (e.g., THF), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures of these solvents with each other or with water.
- a suitable solvent including, but not limited to an alcohol (e.g., ethanol), an ester (e.g., ethyl acetate), an ether (e.g., THF), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures of these solvents with each other or with water.
- the reaction is carried out by mixing a THF solution of compound (IV) with isobutylamine in the presence of a base, such as inorganic base including, but not limited to sodium hydroxide, sodium hydrogen carbonate, soda ash and, potassium or sodium carbonate or an organic base such as a tertiary amine, selected from the group consisting of acyclic amines (e.g., trimethylamine, triethylamine, dimethylphenylamine diisopropylethylamine and tributylamine), cyclic amines (e.g., N-methylmorpholine) and aromatic amines (dimethylaniline, dimethylaminopyridine and pyridine).
- a base such as inorganic base including, but not limited to sodium hydroxide, sodium hydrogen carbonate, soda ash and, potassium or sodium carbonate or an organic base such as a tertiary amine, selected from the group consisting of acyclic amines (e.g., trimethylamine
- an excess of isobutylamine can be used as a base.
- the reaction is carried out at a temperature in the range of about 50° C. to reflux temperature, wherein the reflux temperature depends on the boiling point of the solvent used.
- reaction steps (i) and (ii) can be carried out in a single step without the separation of compound (IV).
- step (iii) is carried out by reacting the compound of formula (V) with a substituted phenylsulfonyl derivative such as a substituted phenylsulfonyl halide, for example, p-aminobenzenesulfonyl chloride, in a suitable solvent selected from a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacetamide), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures thereof or mixtures of any of these solvents with water.
- a suitable solvent selected from a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an
- the reaction is carried out at a temperature in the range of about 20° C. to reflux temperature, wherein the reflux temperature depends on the boiling point of the solvent used.
- the reaction is carried out at a temperature in the range of about 20-35° C. and in the presence of a base selected from inorganic base (e.g., sodium hydroxide, sodium hydrogen carbonate, soda ash, and potassium carbonate), organic base (e.g.
- inorganic base e.g., sodium hydroxide, sodium hydrogen carbonate, soda ash, and potassium carbonate
- organic base e.g.
- tertiary amine including acyclic amines (e.g., trimethylamine, triethylamine, diisopropylamine, tributylamine), cyclic amines (e.g., N-methylmorpholine) and aromatic amines (e.g., dimethylaniline, dimethylaminopyridine and pyridine).
- acyclic amines e.g., trimethylamine, triethylamine, diisopropylamine, tributylamine
- cyclic amines e.g., N-methylmorpholine
- aromatic amines e.g., dimethylaniline, dimethylaminopyridine and pyridine.
- the steps (i), (ii) and (iii) can be combined and carried out in a single step without the need to separate intermediate compounds.
- the present invention provides a process for the stereo-directed synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol comprising the steps of:
- X 1 and X 2 are each independently OH or a leaving group.
- suitable leaving groups include halogens (e.g., Cl, Br, I), or sulfonate leaving groups (e.g., MsO and TsO).
- X 1 and X 2 are each OH.
- Y 1 and Y 2 are each independently a stereo-directing moiety that can be removed under basic or neutral conditions.
- Y 1 and Y 2 are bulky groups.
- stereo-directing moieties that can be removed under basic or neutral conditions include fluorenylmethyloxycarbonyl (Fmoc), p-nitrobenzenesulfoethoxycarbonyl, propargyloxycarbonyl, picolinyl, prenyl, o-nitrobenzyloxy methyl, 4-methyoxyphenoxymethyl, guaiacolmethyl, siloxymethyl, such as triisopropylsiloxymethyl, 2-cyanoethyoxymethyl, 2-quinolinylmethyl, dichloroacetyl, trichloroacetyl, and 2-[4-nitrophenyl]ethylsulfonate.
- the stereodirecting moiety is Fmoc. According to other embodiments, the stereodirecting moiety is not a benzyl ether protecting group, an alkyl ether protective group or a silyl protecting group.
- X 1 and X 2 may be the same or different from each other.
- Y 1 and Y 2 may be the same or different from each other.
- the bulkiness of the stereodirecting groups influences the stereochemistry of aldol condensation towards the desired isomer, i.e., the (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol stereoisomer. It is contemplated that replacing the acid-labile protecting groups known in the art with a bulky stereodirecting group such as Fmoc or similar groups (e.g.
- p-nitrobenzenesulfoethoxycarbonyl has the following advantages: (a) Fmoc derivatives have in general the tendency to form crystals in contrast to the acid-labile protecting groups mentioned in the art; (b) because of strong UV absorption of the Fmoc group, the control of the reaction by TLC and HPLC is easier; (c) removal of Fmoc group is simple and quantitative at neutral conditions (for example, by using of catalytic amount of DBU or fluoride anions as tetrabutylammonium fluoride and pyridine hydrogen fluoride); and above all (d) the presence of bulky Fmoc group will help to perform reaction in the right stereoselective direction.
- the oxidation of compounds VI and VIII is performed by SO 3 -pyridine complex in the presence of triethylamine.
- the solvent in which the process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol takes place is not particularly restricted provided it does not interfere with the reaction.
- suitable solvents include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents, alcohol solvents, ester solvents, water, chlorinated hydrocarbons, protic polar solvents, aprotic polar solvents, mixed solvents, ionic liquids thereof and the like, and any mixtures thereof.
- suitable solvents include aliphatic hydrocarbon solvents, aromatic solvents, ether solvents, alcohol solvents, ester solvents, water, chlorinated hydrocarbons, protic polar solvents, aprotic polar solvents, mixed solvents, ionic liquids thereof and the like, and any mixtures thereof.
- the present invention provides the use of compounds having the structures VI, VII, VIII and IX for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
- the process further comprises the step of converting (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol to darunavir of formula (I).
- the present invention provides the use of compounds having the structures VI, VII, and IX wherein Y 1 and Y 2 are both Fmoc for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
- the present invention provides the use of compounds having the structures VI, VII, VIII and IX wherein Y 1 and Y 2 are both Fmoc for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
- the stereoselective aldol condensation is performed in the presence of a chiral catalyst.
- the chiral catalyst is selected, yet not limited to chiral amino acids and their derivatives, for example, organic and inorganic salts, complexes with metals or peptides.
- the chiral catalyst is a valine.
- the chiral catalyst is a dipeptide.
- the chiral catalyst is other than proline.
- the chiral catalyst is chiral cyclic secondary amine, preferably, proline or 5,5-dimethyl thiazolidinium-4-carboxylic acid.
- the removal of the stereodirecting moieties (Y 1 and Y 2 ) from the product of the stereoselective aldol condensation is performed under basic conditions; alternatively under mild basic conditions; alternatively under neutral conditions, each possibility representing a separate embodiment of the present invention.
- the stereodirecting moieties may be removed under neutral conditions by 1,8-Diazabicycloundec-7-ene (DBU) or by a fluoride anion such as tetrabutylammonium fluoride or pyridine hydrogen fluoride.
- DBU 1,8-Diazabicycloundec-7-ene
- a fluoride anion such as tetrabutylammonium fluoride or pyridine hydrogen fluoride.
- the removal of the stereodirecting moieties may be performed under conditions well known in the art.
- the cyclization of the Y 1 and Y 2 eliminated product to obtain (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol is preferably carried out in the presence of an acid catalyst.
- acid catalysts include Lewis acids such as zinc chloride, aluminium chloride, titanium tetrachloride and the like, inorganic acids, such as hydrochloric acid, hydrofluoric acid, sulfuric acid, tungstic acid, organic acids, such as methanesulfonic acid, p-toluenesulfonic acid, and solid acids, such as acidic ion exchange resins or zeolites.
- the process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol further comprises the conversion of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol to darunavir of formula (I).
- the present invention provides a process for the preparation of darunavir, a compound of formula (I).
- the process involves the synthesis of compound of formula (I) starting from the 3-amino-2-hydroxy-4-phenylbutane derivative of formula (II), comprising the following steps: (i) coupling (II) with a (3R, 3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivate (III), (ii)—reacting the resultant compound (IV) with isobutylamine, and (iii)—coupling the resultant compound (V) with a phenylsulfonyl derivative to form a compound of formula (I).
- Compound (III) may be prepared by reacting (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol with a suitable coupling reagent.
- the present invention further provides a process for preparing (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
- Step (i) involves the coupling of 3-amino-2-hydroxy-4-phenylbutane derivative (compound of formula (II)) with a (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivate (III) to obtain compound of formula (IV).
- the X moiety in the compound of formula (II) is a labile leaving group.
- X 4-Me-Ph, tosylate); lower alkanoate such as acetate, a halogen (e.g., I, Br, Cl), or —N + Me 3 X ⁇ , wherein X may be —OTf, —OTs, —I, —Br, —Cl or —OH.
- halogen e.g., I, Br, Cl
- X may be —OTf, —OTs, —I, —Br, —Cl or —OH.
- X is Cl.
- step (i) is carried out by reacting the compound of formula (II) with a (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivate, for example in an organic solvent selected from a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacetamide), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures thereof.
- an organic solvent selected from a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacetamide), a chlorinated solvent (e.g.,
- the organic solvent is dichloromethane or THF.
- the (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivate is (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl imidazolyl carbonate.
- the (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivate is (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl oxysuccinimide carbonate.
- the reaction is carried out at a temperature in the range of about 20° C. to reflux temperature, wherein the reflux temperature depends on the boiling temperature of the solvent used. According to a currently preferred embodiment, the reaction is carried out at a temperature in the range of about 20-60° C., with dichloromethane or THF as the preferred solvent.
- X in the compound of formula (II) is Cl.
- the compound of formula (II) is designated (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane.
- the compound of formula (II) can be used as a free base or, according to some embodiments, in the form of salt.
- the salt is a hydrochloride salt.
- Some of the compounds of formula (II) are commercially available (e.g., (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane hydrochloride).
- compounds of formula (II) may be prepared by several ways available in the literature (for example see a) Tetrahedron Letters, 1995, 36(19); 3317-20 and b) Org. Biomol. Chem., 2004, 2:2061-70).
- the R moiety in the compound of formula (III) is halogen (e.g., —F, —Cl, —Br, —I), imidazolyl, benzotriazolyl, oxysuccinimidyl, oxybenzotriazolyl, 4-nitrophenoxy, 4-methoxyphenoxy, 2-nitrophenoxy, pentafluorophenoxy or other analogous groups, usually used for formation of active esters.
- halogen e.g., —F, —Cl, —Br, —I
- the compound of formula (III) above can be prepared from (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol in a conventional manner, for example as described in WO 2005/000249.
- the (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol is suitably activated with a coupling agent RCO—Y wherein Y is a leaving group such as described above for the substituents X, to generate a hexahydrofuro[2,3-b]furan-3-yl derivative (III) which is then coupled with the compound of formula (II) to obtain the compound (IV).
- Non-limiting examples of coupling agents that may be used in the preparation of compound (III) are carbonates such as bis-(4-nitrophenyl)carbonate, disuccinimidyl carbonate (DSC), vinylene carbonate, ethylene carbonate, C 1 -C 4 dialkyl carbonate and 2-(S),3-pyridinediyl carbonate; chloroformates such as phenyl chloroformate, trichloromethyl chloroformate, phenyl tetrazoylformate and p-nitrophenylchloroformate; carbonyl diimidazole (CDI); oxalyl chloride (ethanedioyl dichloride); phosgene; diphosgene or triphosgene.
- carbonates such as bis-(4-nitrophenyl)carbonate, disuccinimidyl carbonate (DSC), vinylene carbonate, ethylene carbonate, C 1 -C 4 dialkyl carbonate and 2-(S),3-
- (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl-imidazolylcarbonate (compound of formula IIIA) is obtained upon reaction of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol with carbonyl diimidazole,
- step (ii) is carried out by reacting the compound of formula (IV) with isobutylamine to form compound (V), with isobutylamine as a solvent or in a suitable solvent including, but not limited to an alcohol (e.g., ethanol), an ester (e.g., ethyl acetate), an ether (e.g., THF), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures of these solvents with each other or with water.
- a suitable solvent including, but not limited to an alcohol (e.g., ethanol), an ester (e.g., ethyl acetate), an ether (e.g., THF), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures of these solvents with each other or with water.
- an alcohol e
- the reaction is carried out by mixing a THF solution of compound (IV) with isobutylamine in the presence of a base, such as inorganic base including, but not limited to sodium hydroxide, sodium hydrogen carbonate, soda ash and, potassium or sodium carbonate or an organic base such as a tertiary amine, selected from the group consisting of acyclic amines (e.g., trimethylamine, triethylamine, dimethylphenylamine, diisopropylethylamine and tributylamine), cyclic amines (e.g., N-methylmorpholine) and aromatic amines (dimethylaniline, dimethylaminopyridine and pyridine).
- a base such as inorganic base including, but not limited to sodium hydroxide, sodium hydrogen carbonate, soda ash and, potassium or sodium carbonate or an organic base such as a tertiary amine, selected from the group consisting of acyclic amines (e.g., trimethyl
- an excess of isobutylamine can be used as a base.
- the reaction is carried out at a temperature in the range of about 50° C. to reflux, wherein the reflux temperature depends on the boiling point of the solvent used.
- reaction steps (i) and (ii) can be carried out in a single step without the separation of compound (IV).
- the synthesis of compound of formula (III), step (i) and step (ii) can be carried out in a single step without the separation of compound (III) or compound (IV).
- step (iii) is carried out by reacting the compound of formula (V) with a substituted phenylsulfonyl halide, for example, p-aminobenzenesulfonyl chloride, in a suitable solvent selected from a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacetamide), a chlorinated solvent (e.g., dichloromethane) and other solvents such as acetonitrile or toluene or mixtures thereof or mixtures of any of these solvents with water.
- a suitable solvent selected from a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacet
- the reaction is carried out at a temperature in the range of about 30° C. to reflux temperature, wherein the reflux temperature depends on the boiling point of the solvent used. According to some currently preferred embodiments, the reaction is carried out at a temperature in the range of about 20-35° C.
- a base selected from inorganic base (e.g., sodium hydroxide, sodium hydrogen carbonate, soda ash, and potassium carbonate), organic base (e.g., tertiary amine, including acyclic amines (e.g., trimethylamine, triethylamine, diisopropylamine, tributylamine), cyclic amines (e.g., N-methylmorpholine) and aromatic amines (e.g., dimethylaniline, dimethylaminopyridine and pyridine).
- inorganic base e.g., sodium hydroxide, sodium hydrogen carbonate, soda ash, and potassium carbonate
- organic base e.g., tertiary amine, including acyclic amines (e.g., trimethylamine, triethylamine, diisopropylamine, tributylamine), cyclic amines (e.g., N-methylmorpholine) and aromatic amines (e.g.
- Benzenesulfonyl derivatives such as, p-aminobenzenesulfonyl chloride, are known in the art, for example, for the preparation of b 3 adrenoreceptor agonists (R. J. Steffan e.a. Bioorganic & Medicinal Chemistry Letters, 12 (2002) 2963-2967).
- Benzenesulfonyl derivatives may be produced by the methods described in British Polymer Journal (1980), 12(4), 192-8, JP09124629, Journal of Chemical Research, Synopses, (8), 493-494; 2003.
- steps (i), (ii) and (iii) can be combined and carried out in a one-pot reaction without the need to separate intermediate compounds.
- the synthesis of compound of formula (III), steps (i), (ii) and (iii) can be combined and carried out in a one-pot reaction without the need to separate intermediate compounds.
- the reaction of step (iii) may be used for the preparation of analogs and derivatives of compound (I) examples of which were found to be potent biological active compounds, especially as HIV protease inhibitors, for example, J. F. Miller et al. Bioorganic & Medicinal Chemistry Letters 14 (2004) 959-963; WO 2005/110428, WO 2007/060253; WO 2005/087728 and WO 2004/016619.
- WO 2006/132390 discloses the synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol, via a reaction of protected 2-oxyacetaldehyde with protected 4-oxybutylaldehyde in the presence of cyclic secondary amine, namely, L-proline, followed by a simultaneous removal of the protecting groups by acid and cyclization of formed hydroxyaldehyde derivative to hexahydrofuro[2,3-b]furan-3-ol.
- cyclic secondary amine namely, L-proline
- stereocontrolling groups do not act simply as passive spectators; stereocontrolling groups are chiral and conformationally flexible, attributes which enable them to be inserted between the stereogenic centre (also known as the ‘chiral center’) and the prochiral reactive center. Steric interactions between the functional group of the stereogenic centre and the stereocontrolling group serve to fixate the relative 1,2-stereochemistry antiperiplanar of the intermediate, thus directing any incoming reactant at the prochiral center located anti to the conformationally mobile group.
- isomeric form “stereochemically isomeric forms” or “stereoisomeric forms”, as used herein, define all possible isomeric as well as conformational forms, made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which compounds or intermediates obtained during said process may possess.
- Isomers include diastereoisomers, epimers, enantiomers and/or conformers of the basic molecular structure of said compound.
- stereogenic centers also referred to as chiral centers
- diastereoisomers may have a syn- or anti-configuration
- substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration
- alkenyl radicals may have the E or Z-configuration.
- diastereomer or “diastereomeric form” applies to molecules with identical chemical constitution and containing more than one stereocenter, which differ in configuration at one or more of these stereocenters.
- stereocenter refers to molecules with identical chemical constitution and containing more than one stereocenter, but which differ in configuration at only one of these stereocenters.
- stereoisomerically pure compounds or stereopure compound relate to compounds having a stereoisomeric excess of at least about 50% (i.e. minimum of about 75% of one isomer and maximum of about 25% of the other possible isomers) up to a stereoisomeric excess of about 100% (i.e.
- stereocontrolling group or “stereodirecting group” may be used interchangeably and refer to chemical groups, which when present during a chemical reaction control or direct the chemical process in such a way as to obtain a reaction product which is highly stereo-pure.
- stereo-controlling or stereo-directing groups include: fluorenylmethyloxycarbonyl (Fmoc), p-nitrobenzenesulfoethoxycarbonyl, propargyloxycarbonyl, picolinyl, prenyl, o-nitrobenzyloxy methyl, 4-methyoxyphenoxymethyl, guaiacolmethyl, siloxymethyl, such as triisopropylsiloxymethyl, 2-cyanoethyoxymethyl, 2-quinolinylmethyl, dichloroacetyl, trichloroacetyl and 2-[4-nitrophenyl]ethylsulfonate (See for example, Tetrahedron: Asymmetry, 2002, 13(24) 2703-26;
- the process for the stereo-directed synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol comprises the following steps:
- X 1 and X 2 are each independently OH or a labile leaving group.
- Y 1 and Y 2 are each independently a stereodirecting moiety that can be removed under basic or neutral conditions. According to some other embodiments, Y 1 and Y 2 may also be removed under acidic conditions.
- Y 1 and Y 2 are bulky groups.
- a stereodirecting moiety that can be removed under basic or neutral conditions include fluorenylmethyloxycarbonyl (Fmoc), p-nitrobenzenesulfoethoxycarbonyl, propargyloxycarbonyl, picolinyl, prenyl, o-nitrobenzyloxy methyl, 4-methyoxyphenoxymethyl, guaiacolmethyl, siloxymethyl, such as triisopropylsiloxymethyl, 2-cyanoethyoxymethyl, 2-quinolinylmethyl, dichloroacetyl, trichloroacetyl and 2-[4-nitrophenyl]ethylsulfonate.
- the stereodirecting moiety is Fmoc. According to some other embodiments, the stereodirecting moiety is not a benzyl ether protecting group, an alkyl ether protective group or a silyl protecting group.
- the precursors of formula HO—CH 2 —CH 2 —X 1 or HO—(CH2) 4 —X 2 are reacted with a reagent containing the groups Y 1 or Y 2 .
- a reagent containing the groups Y 1 or Y 2 .
- the reagent can be fluorenylmethyloxycarbonyl chloride or anhydride.
- reagents that can be used to introduce the bulky stereodirecting groups include, but are not limited to p-nitrobenzenesulfoethoxycarbonyl chloride, propargyloxycarbonyl chloride, picolinoyl chloride, prenyl chloride, (2-nitrophenyl)methoxymethyl, 4-(methyoxyphenoxy)-methyl chloride, guaiacolmethyl chloride, siloxymethyl chloride, triisopropylsiloxymethyl chloride, 2-cyanoethyoxymethyl chloride, 2-quinolinylmethyl chloride, dichloroacetyl chloride, trichloroacetyl chloride and 2-[4-nitrophenyl]ethylsulfonyl chloride.
- the reaction of steps (a) and (c) is preferably carried out at ambient temperature (i.e., about 20-25° C.) and in the presence of a base selected from organic base (e.g., tertiary amine, including acyclic amines (e.g., trimethylamine, triethylamine, diisopropylamine, tributylamine), cyclic amines (e.g., N-methylmorpholine), inorganic base (e.g., sodium hydroxide, sodium hydrogen carbonate, soda ash, and potassium carbonate), and aromatic amines (e.g., dimethylaniline, dimethylaminopyridine and pyridine).
- a base selected from organic base (e.g., tertiary amine, including acyclic amines (e.g., trimethylamine, triethylamine, diisopropylamine, tributylamine), cyclic amines (e.g., N-methylmorpho
- the reaction of steps (a) and (c) is carried out in an organic solvent selected from a chlorinated solvent (e.g., dichloromethane); a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacetamide), and other solvents such as acetonitrile or toluene or mixtures thereof.
- the organic solvent is a chlorinated solvent, preferably dichloromethane.
- the oxidation of compounds VI and VIII is performed by a reagent selected from the group consisting of: SO 3 -pyridine complex in the presence of triethylamine and/or DMSO, acetyl chloride or anhydride and DMSO, trifluoroacetyl chloride or anhydride and DMSO, methanesulfonyl chloride and DMSO or tetrahydro thiophene-S-oxide, toluenesulfonyl bromide and DMSO, trifluoro-methanesulfonyl anhydride (triflic anhydride) and DMSO, phosphorus pentachloride and DMSO, dimethylphosphoryl chloride and DMSO, isobutyl chloroformate and DMSO, manganese dioxide, copper oxide, dimethyl sulphoxide activated with oxalyl chloride (N.
- a reagent selected from the group consisting of: SO 3 -pyridine
- the oxidation of compounds VI and VIII is performed by SO 3 -pyridine complex in the presence of triethylamine and DMSO.
- Other tertiary bases such as diisopropylethylamine, N-methylmorpholine can be used instead of triethylamine.
- the reaction of steps (b) and (d) is preferably carried out at a temperature range of ⁇ 10° C. and 20° C.; preferably between ⁇ 5° C. and 15° C.; most preferably between 0° C. and 10° C.
- the reaction of steps (b) and (d) is carried out in DMSO or mixture DMSO with an organic co-solvent selected from a chlorinated solvent (e.g., dichloromethane), a ketone (e.g., acetone), an ester (e.g., ethyl acetate), an ether (e.g., THF), an amide (e.g., dimethylformamide or dimethylacetamide), and other solvents such as acetonitrile or toluene or mixtures thereof.
- the organic co-solvent is toluene.
- the stereoselective aldol condensation is performed in the presence of a chiral catalyst.
- the chiral catalyst is selected, yet not limited to chiral amino acids and their derivatives, for example, organic and inorganic salts, complexes with metals or peptides.
- the chiral catalyst is a valine.
- the chiral catalyst is a dipeptide.
- the chiral catalyst is other than proline.
- the chiral catalyst is chiral cyclic secondary amine, preferably, proline or 5,5-dimethyl thiazolidinium-4-carboxylic acid.
- the chiral catalyst may be any chiral catalyst known in the art, such as
- the reaction of step (e) is preferably carried out at a temperature range of about 0° C. to about 10° C.; preferably at a temperature of about 4° C.
- the compound of formula VII is preferably present as about 1 to about 3 equivalents of the compound of formula IX, and more preferably as 2 equivalents of the compound of formula IX.
- the compound of formula IX may be present in molar excess over the compound of formula VII.
- the reaction of steps (b) and (d) is carried out in an organic solvent, preferably an amide such as dimethylformamide or dimethylacetamide.
- the chiral catalyst is preferably present as about 0.05 to about 0.5 equivalents of the compound of formula IX, more preferably as 0.05 to 0.2 equivalents, yet more preferably as 0.1 equivalent.
- the chiral catalyst is preferably present as about 0.05 to about 0.5 equivalents of the of the compounds of formula VII, more preferably as about 0.05 to about 0.2 equivalents, yet more preferably as 0.1 equivalent.
- the removal of the stereodirecting moieties (Y 1 and Y 2 ) from the product of the stereoselective aldol condensation is performed under basic conditions; alternatively under mild basic conditions; alternatively under neutral conditions.
- the stereodirecting moieties may be removed under basic conditions by 1,8-Diazabicycloundec-7-ene (DBU) or by a fluoride anion such as tetrabutylammonium fluoride or pyridine hydrogen fluoride.
- DBU 1,8-Diazabicycloundec-7-ene
- a fluoride anion such as tetrabutylammonium fluoride or pyridine hydrogen fluoride.
- Other suitable bases may include, but are not limited to inorganic bases such as alkali metal, alkali earth metal, and ammonium hydroxides and alkoxides.
- Suitable bases are lithium diisopropyl amide, sodium methoxide, potassium methoxide, lithium methoxide, potassium t-butoxide, calcium dihydroxide, barium dihydroxide, and quaternary alkylammonium hydroxides, DBN (1,3-diazabicyclo[3.4.0]non-5-ene), DABCO (1,4-diazabicyclo[2.2.2]octane), TBAF, TMG, potassium carbonate and sodium carbonate or mixtures thereof.
- the removal of the stereodirecting moieties may be performed under conditions well known in the art.
- One advantage of the process of the present invention is that the removal of the Y 1 and Y 2 groups under neutral and basic conditions allows for the purification of the hydroxyaldehyde intermediate before cyclization.
- protective groups which can be removed only under acidic conditions, such intermediate purification is not possible as cyclization spontaneously occurs under acidic conditions.
- acid catalysts include Lewis acids such as zinc chloride, aluminium chloride, titanium tetrachloride and the like, inorganic acids, such as hydrochloric acid, hydrofluoric acid, sulfuric acid, tungstic acid, organic acids, such as methanesulfonic acid, p-toluenesulfonic acid, and solid acids, such as acidic ion exchange resins or zeolites.
- the solid acids may be metal oxide systems in gel form (solid/gel systems), for example SiO 2 , GeO 2 , B 2 O 3 , Al 2 O 3 , TiO 2 , ZrO 2 and combinations thereof.
- such solid/gel systems may be further treated with an acid, preferably a dibasic acid or tribasic acid, such as, for example, H 2 SO 4 , H 3 PO 4 or orthophosphoric acid.
- Suitable acid catalysts are, for example, HBr, HI, HClO 4 , HBF 4 , HPF 6 , HAsF 6 , HSbCl 6 , HSbF 6 and HBPh 4 , aliphatic and aromatic optionally halogenated (fluorinated or chlorinated) carboxylic acids, sulfonic acids and phosphorus (V) acids (e.g., phosphonic acids or phosphonous acids), formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, phenylacetic acid, cyclohexanecarboxylic acid, mono-, di- and tri-chloroacetic acid, mono-, di- and tri-fluoroacetic acid, chlorobenzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, chlorobenzenesulfonic acid, tri
- the solid acids may be inorganic or organic ion exchangers that have been treated with a dibasic acid or tribasic acid, such as, for example, H 2 SO 4 , H 2 S 2 O 7 or H 3 PO 4 .
- the organic ion exchangers are polymers having acidic groups, such as for example —C(O)OH, —SO 3 H or —PO 3 H (e.g., Nafion), some of which are commercially available.
- the inorganic ion exchangers are natural and synthetic aluminosilicates (e.g. zeolites), some of which are commercially available (e.g., Zeolith ZSM-5, Zeolith Y and mordenite).
- the solid acids are natural or synthetic silicate-like minerals that have no or only limited ion exchanging properties.
- examples are phyllosilicates and argillaceous earths, for example montmorillonite, hectorite, vermicullite, kaolinite and illite.
- the silicates and argillaceous earths may additionally be impregnated with an acid, preferably a dibasic acid or a tribasic acid, such as, for example, H 2 SO 4 , H 2 S 2 O 7 and H 3 PO 4 .
- suitable acids have been mentioned above.
- the solid acids may be heteropoly acids which preferably comprise the elements Mo, V, W, O and H.
- phosphotungstic acid for example, tungstic acid, tungstosilicic acid and molybdophosphoric acid.
- the steps (a-f) can be combined and carried out in a single step without the need to separate intermediate compounds. Alternatively, some, but not all, of the steps (a-f) are combined and carried out in a single step.
- 1,1′-carbonyldiimidazole (162.15 g, 1 mol) was added to THF (0.5 L), following by solution of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (135.2 g, 1.04 mol) in 0.3 L of THF and the mixture was stirred for a further hour.
- (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane hydrochloride (229 g, 0.97 mol) was added and the mixture heated at 55-60° C. approximately 5-6 hours under TLC control (for complete disappearance of (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane).
- 1,1′-carbonyldiimidazole (162.15 g, 1 mol) was added to THF (0.5 L), following by solution of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (135.2 g, 1.04 mol) in 0.3 L of THF and the mixture was stirred for a further hour.
- (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane hydrochloride (229 g, 0.97 mol) was added and the mixture heated at 55-60° C. approximately 5-6 hours under TLC control (for complete disappearance of (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane).
- the obtained product may be used without further purification in the next step or it may be purified by crystallization or by flash chromatography giving the mono-protected alcohol in >95% purity and 83-92% yield (calculated based on Fmoc-Cl).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
-
- (i) amidation of (1-oxiranyl-2 phenyl-ethyl)-carbamic acid tert-butyl ester with isopropylamine according to the following scheme:
-
- (ii) introducing a p-nitrophenylsulfonyl group in the resultant compound of step (i) according to the following scheme:
-
- (iii) reducing the nitro moiety of the resultant compound of step (ii) according to the following scheme:
-
- (iv) deprotecting the resultant compound of step (iii) according to the following scheme:
-
- (v) Coupling the resultant compound of step (iv) with a (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl derivate, to form compound of formula (I) according to the following scheme:
wherein X is a leaving group. Non-limiting examples of leaving groups include a halogen (e.g., Cl, Br, I) or a sulfonate leaving group (e.g., MsO and TsO). According to some embodiments, X is Cl.
wherein R is halogen (e.g., Cl, Br, I), imidazolyl, benzotriazolyl, oxysuccinimidyl, oxybenzotriazolyl, 4-nitrophenoxy, 4-methoxyphenoxy, 2-nitrophenoxy, pentafluorophenoxy or other analogous groups typically used for formation of active esters.
-
- (a) reacting an ethanol derivative of the general formula HO—CH2—CH2—X1, with a reagent comprising a stereo-controlling (stereo-directing) moiety (Y1) to obtain a compound having the formula (VI):
HO—CH2—CH2—OY1 VI - wherein X1 is OH or a leaving group and the stereodirecting moiety Y1 is removable under neutral or basic conditions;
- (b) oxidizing compound (VI) to obtain an aldehyde having the formula (VII);
O═CH—CH2—OY1 VII - (c) reacting a butanol derivative of the general formula HO—(CH2)4—X2, with a reagent comprising a stereodirecting moiety (Y2) to obtain a compound having the formula (VIII);
HO—(CH2)4—OY2 VIII - wherein X2 is OH or a leaving group and the stereodirecting moiety Y2 is removable under neutral or basic conditions;
- (d) oxidizing compound (VIII) to obtain an aldehyde having the formula (IX);
O═CH—(CH2)3—OY2 IX - (e) stereoselectively coupling compounds (VII) and (IX) in the presence of a chiral catalyst to form a compound of formula (X);
- (a) reacting an ethanol derivative of the general formula HO—CH2—CH2—X1, with a reagent comprising a stereo-controlling (stereo-directing) moiety (Y1) to obtain a compound having the formula (VI):
-
-
- wherein the coupling step is preferably by aldol condensation; and
- (f) removing the stereodirecting moieties (Y1 and Y2) from the product of step (e) followed by cyclization in the presence of a catalyst (preferably an acid catalyst) to form (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
-
-
- (a) reacting an ethanol derivative of the general formula HO—CH2—CH2—X1, with a reagent comprising a stereocontrolling (stereodirecting) moiety (Y1) to obtain a compound having the formula (VI):
HO—CH2—CH2—OY1 VI - wherein X1 is OH or a leaving group and the stereodirecting moiety Y1 is preferably removable under neutral or basic conditions;
- (b) oxidizing compound (VI) to obtain an aldehyde having the formula (VII);
O═CH—CH2—OY1 VII - (c) reacting butanol derivative of the general formula HO—(CH2)4—X2 with a reagent comprising a stereodirecting moiety (Y2) to obtain a compound having the formula (VIII)
HO—(CH2)4—OY2 VIII; - wherein X2 is OH or a leaving group and the stereodirecting moiety Y2 is preferably removable under neutral or basic conditions;
- (d) oxidizing compound (VIII) to obtain an aldehyde having the formula (IX);
O═CH—(CH2)3—OY2 IX - (e) stereoselectively coupling compounds (VII) and (IX), preferably by aldol condensation in the presence of a chiral catalyst to form a compound of formula (X);
- (a) reacting an ethanol derivative of the general formula HO—CH2—CH2—X1, with a reagent comprising a stereocontrolling (stereodirecting) moiety (Y1) to obtain a compound having the formula (VI):
-
-
- and
- (f) removing the stereodirecting moieties (Y1 and Y2) from the product of step (e) followed by cyclization in the presence of a catalyst (preferably an acid catalyst) to form (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.
-
H4Xn+M12O40,X═Si,Ge;M=Mo,WH3Xn+M12O40,X═P,As;M=Mo,WH6X2M18O62,X═P,As;M=Mo,W;
- 1. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (100 mg) was added into a pre-dried 25 ml round bottom flask under nitrogen. Disuccinimidyl carbonate (DSC) (295 mg) was then added followed by acetonitrile (3 ml). Et3N (155 mg) was added while stirring, until the suspension became clear. The resulting solution was stirred at ambient temperature for 5 hours under TLC control. The solvent was then removed, saturated solution of NaHCO3 (4 ml) was added, and extracted with EtOAc (3*20 ml). The combined organic fractions were dried with Na2SO4, filtered, and concentrated to an oily residue. MeOH (4 ml) was added, and the resulting suspension was stirred, then filtered and dried to give 152 mg of compound III as a white solid.
- 2. Compound III from above (125 mg) was added into a pre-dried 25 ml round bottom flask under nitrogen. (2S,3S)-3-amino-1-chloro-2-hydroxy-4-phenylbutane hydrochloride (94 mg), Et3N (0.4 ml), and CH2Cl2 (20 ml) were added and stirred at ambient temperature for 3 hours, under TLC control. The solvent was then filtered, the organic layer was washed with 5% NaH2PO4 (5 ml) and with water (15 ml), then dried over Na2SO4, filtered and concentrated to give 120 mg of compound 5 as a white solid. NMR spectrum corresponded to structure.
- 1. A mixture from previous step, isobutylamine 73.8 g (1.01 mol) and sodium hydrogen carbonate (92.4, 1.1 mol) in water (1 L) was heated at a gentle reflux (˜60° C.) with stirring until reaction completed under TLC control (˜5 h). Excess isobutyl amine and THF were removed by distillation under nitrogen at an internal reaction temperature of 70-75° C. Additional water (500 g) was added and the product was isolated by filtration, washed with water and dried in vacuum, yielded 360 g (92%) of white to off-white solid, MS: m/z 393 (MH+), 427 [M+Cl]−, NMR spectrum corresponded to structure.
- 2. Compound IV (100 mg) and isobutylamine (2 ml) were added into a pre-dried 10 ml round bottom flask. The reaction was heated to 60° C. overnight under TLC control. The excess isobutylamine was evaporated and the residue was subjected to column chromatography (eluent: MeOH:CH2Cl2, 1:10) to give 80 mg of the product. MS: m/z 393 (MH+), 427 [M+Cl]−, NMR spectrum corresponded to structure.
- a) A solution of Fmoc-acetaldehyde (2.0 mmol, 2 equiv) in DMF (500 mL) was added slowly over the course of 2.5 h to a stirring mixture of Fmoc-n-butyraldehyde (1.0 mmol, 1 equiv) and (S)-proline (0.10 mmol, 0.1 equiv) in DMF (500 mL) at 4° C. The resulting mixture was stirred for 16 h at the same temperature. The reaction progress was monitored by TLC. When the reaction was terminated, a catalytic amount of DBU was added and the mixture was stirred at 1-2 h under TLC control. Upon reaction termination (removal of the Fmoc group), a brown-colored reaction mixture was obtained. The product was then filtered, and the filtrate was evaporated under high vacuum at 22-30° C. (bath temperature). The residue was dissolved in water (0.5 L) and extracted with toluene or hexane.
- b) To the aqueous solution from step (a) 300 g of 3-5% wt aq. HCl were added at 2-5° C. Stirring was continued for additional 20 h, then 38 g of pyridine, 2000 g toluene and 650 ml water were added. After additional 1 h stirring, the mixture was filtered over a decalite pre-coated filter. The toluene layer was extracted with 4×600 ml water and the combined aqueous phase was washed with 1200 g toluene. The aqueous phase was then concentrated under vacuum to about 850 ml, which were then extracted with ethyl acetate six times, each time with 1500 ml; the combined organic layer was washed with 450 ml water, 400 ml 5% HCl and 500 ml of 5% sodium carbonate and then dried with 1000 g Na2SO4. The organic layer (ethyl acetate) was concentrated under vacuum, and 160.2 g of brown oil were obtained, corresponding to a yield of 85% based on the mono-protected butyraldehyde, with enantiomeric purity of >95%. The required product was further purified by Flash chromatography.
Claims (25)
HO—CH2—CH2—OY1 VI
O═CH—CH2—OY1 VII
HO—(CH2)4—OY2 VIII
O═CH—(CH2)3—OY2 IX;
HO—CH2—CH2—OY1 VI
O═CH—CH2—OY1 VII
HO—(CH2)4—OY2 VIII
O═CH—(CH2)3—OY2 IX
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/519,297 US8829208B2 (en) | 2010-01-28 | 2011-01-24 | Process for the preparation of darunavir and darunavir intermediates |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29894110P | 2010-01-28 | 2010-01-28 | |
ILPCT/IL2010/000533 | 2010-07-01 | ||
WOPCT/IL2010/000533 | 2010-07-01 | ||
IL2010000533 | 2010-07-01 | ||
PCT/IL2011/000079 WO2011092687A1 (en) | 2010-01-28 | 2011-01-24 | Process for the preparation of darunavir and darunavir intermediates |
US13/519,297 US8829208B2 (en) | 2010-01-28 | 2011-01-24 | Process for the preparation of darunavir and darunavir intermediates |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120296101A1 US20120296101A1 (en) | 2012-11-22 |
US8829208B2 true US8829208B2 (en) | 2014-09-09 |
Family
ID=44318738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/519,297 Active 2031-03-11 US8829208B2 (en) | 2010-01-28 | 2011-01-24 | Process for the preparation of darunavir and darunavir intermediates |
Country Status (11)
Country | Link |
---|---|
US (1) | US8829208B2 (en) |
EP (1) | EP2528923B1 (en) |
JP (1) | JP2013518096A (en) |
CN (1) | CN102725295A (en) |
AU (1) | AU2011210349A1 (en) |
BR (1) | BR112012018862A2 (en) |
CA (1) | CA2784398A1 (en) |
ES (1) | ES2516916T3 (en) |
MX (1) | MX2012008627A (en) |
PL (1) | PL2528923T3 (en) |
WO (1) | WO2011092687A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8921415B2 (en) | 2009-01-29 | 2014-12-30 | Mapi Pharma Ltd. | Polymorphs of darunavir |
WO2011051978A2 (en) | 2009-10-30 | 2011-05-05 | Lupin Limited | A novel process for preparation of darunavir and darunavir ethanolate of fine particle size |
MX2012008627A (en) | 2010-01-28 | 2012-09-21 | Mapi Pharma Ltd | Process for the preparation of darunavir and darunavir intermediates. |
EP3795572B1 (en) | 2012-07-24 | 2023-11-15 | Laurus Labs Limited | Darunavir propionate solvate |
CN105085323B (en) * | 2014-05-14 | 2017-02-15 | 重庆圣华曦药业股份有限公司 | Novel synthesis process of Darunavir intermediate |
CN105315178B (en) * | 2014-07-09 | 2018-07-06 | 浙江九洲药业股份有限公司 | Prezista related substances and preparation method thereof |
JP6435907B2 (en) * | 2015-02-16 | 2018-12-12 | 住友化学株式会社 | Method for producing hexahydrofurofuranol derivative |
CN113307783B (en) * | 2016-05-07 | 2023-04-07 | 成都博腾药业有限公司 | Method for preparing darunavir intermediate |
CN108226329A (en) * | 2017-12-25 | 2018-06-29 | 浙江天宇药业股份有限公司 | The liquid phase chromatography analytical method of L- prolineamides |
Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415747A (en) | 1981-09-29 | 1983-11-15 | Union Carbide Corporation | Process for making ethylene glycol derivatives |
WO1994004492A1 (en) | 1992-08-25 | 1994-03-03 | G.D. Searle & Co. | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
WO1995006030A1 (en) | 1993-08-24 | 1995-03-02 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
EP0754669A1 (en) | 1995-02-03 | 1997-01-22 | Kaneka Corporation | Processes for producing alpha-halo ketones, alpha-halohydrins and epoxides |
JPH09124629A (en) | 1995-10-26 | 1997-05-13 | Kissei Pharmaceut Co Ltd | Production of tetrahydrofuryl carbamate derivative |
US5830897A (en) | 1992-08-27 | 1998-11-03 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
WO1999067254A2 (en) | 1998-06-23 | 1999-12-29 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Multi-drug resistant retroviral protease inhibitors and use thereof |
WO1999067417A2 (en) | 1998-06-23 | 1999-12-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fitness assay and associated methods |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6046190A (en) | 1992-08-25 | 2000-04-04 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
EP1029856A1 (en) | 1998-08-25 | 2000-08-23 | Kaneka Corporation | Process for the preparation of (2r, 3s)-3-amino-1,2-oxirane |
EP1067125A1 (en) | 1999-01-29 | 2001-01-10 | Kaneka Corporation | PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES |
EP1081133A1 (en) | 1999-08-31 | 2001-03-07 | Ajinomoto Co., Inc. | Method for producing N-carbamate-protected beta-aminoepoxide and beta-aminoalcohol |
US20020026079A1 (en) | 2000-08-16 | 2002-02-28 | David Kronenthal | Process for the preparation of alpha' chloroketones |
EP1215209A1 (en) | 2000-12-12 | 2002-06-19 | Ajinomoto Co., Inc. | Method for the production of a crystalline epoxide |
WO2003022853A1 (en) | 2001-09-10 | 2003-03-20 | Tibotec Pharmaceuticals Ltd. | Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol |
WO2003024974A2 (en) | 2001-09-20 | 2003-03-27 | Smithkline Beecham Corporation | Process for preparing protease inhibitor intermediates |
WO2003060905A1 (en) | 2001-12-30 | 2003-07-24 | Lang Juergen K | System and method for the production and distribution of copy-protected and use-protected electronic audio and visual media and the data contents thereof |
US6613743B2 (en) | 1998-06-19 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
WO2003106461A2 (en) | 2002-05-16 | 2003-12-24 | Tibotec Pharmaceuticals Ltd | Pseudopolymorphic forms of a hiv protease inhibitor |
WO2004016619A1 (en) | 2002-08-14 | 2004-02-26 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
WO2004033462A2 (en) | 2002-10-09 | 2004-04-22 | The Board Of Trustees Of The University Of Illinois | METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS |
US20040162340A1 (en) | 2002-12-27 | 2004-08-19 | Sumika Fine Chemicals Co., Ltd. | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof |
WO2004094465A2 (en) | 2003-04-23 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign | Synthetic molecules that mimic chemokines |
WO2005000249A2 (en) | 2003-06-27 | 2005-01-06 | Smithkline Beecham Corporation | Preparation of chemical compounds |
US6852887B2 (en) | 1999-12-23 | 2005-02-08 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-P-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
WO2005063770A1 (en) | 2003-12-23 | 2005-07-14 | Tibotec Pharmaceuticals Ltd. | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
WO2005087728A1 (en) | 2004-03-11 | 2005-09-22 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
WO2005095410A1 (en) | 2004-03-31 | 2005-10-13 | Tibotec Pharmaceuticals Ltd. | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL |
WO2005110428A2 (en) | 2004-05-07 | 2005-11-24 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
US20060135562A1 (en) | 2004-11-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and darunavir |
US20060135563A1 (en) | 2004-12-01 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and SCH-417690 |
WO2006108879A2 (en) | 2005-04-15 | 2006-10-19 | Tibotec Pharmaceuticals Ltd. | Use of a sulfonamide compound for improving the pharmacokinetics of a drug |
US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
WO2006132390A1 (en) | 2005-06-06 | 2006-12-14 | Sumitomo Chemical Company, Limited | Method for producing hexahydrofurofuranol derivative |
US20070060642A1 (en) | 2003-12-23 | 2007-03-15 | Goyvaerts Nicolaas Martha Feli | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
WO2007060253A1 (en) | 2005-11-28 | 2007-05-31 | Tibotec Pharmaceuticals Ltd. | Substituted aminophenylsulfonamide compounds as hiv protease inhibitor |
WO2007126812A2 (en) | 2006-03-29 | 2007-11-08 | Gilead Sciences, Inc. | Process for preparation of hiv protease inhibitors |
WO2008016522A2 (en) | 2006-07-24 | 2008-02-07 | Gilead Sciences, Inc. | Hiv reverse transcriptase inhibitors |
WO2008034598A1 (en) | 2006-09-19 | 2008-03-27 | Dsm Ip Assets B.V. | Method for the synthesis of hexahydrofuro (2, 3-b) furan-3-ol compounds |
WO2008055970A2 (en) | 2006-11-09 | 2008-05-15 | Tibotec Pharmaceuticals Ltd. | Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol |
WO2008132154A1 (en) | 2007-04-27 | 2008-11-06 | Tibotec Pharmaceuticals Ltd. | Methods for the preparation of n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives |
WO2009000853A2 (en) | 2007-06-25 | 2008-12-31 | Tibotec Pharmaceuticals Ltd. | Combination formulations comprising darunavir and etravirine |
WO2009005674A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
WO2009030733A1 (en) | 2007-09-04 | 2009-03-12 | Dsm Ip Assets B.V. | Method for the synthesis of 4-alkoxy-, 4-hydroxy- and 4-aryloxy-substituted tetrahydro-furo[3,4-b]furan-2(3h)-one compounds |
US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
WO2009081174A2 (en) | 2007-12-24 | 2009-07-02 | Cipla Limited | Anti - retroviral combination |
WO2010002998A1 (en) | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
WO2010023322A1 (en) | 2008-09-01 | 2010-03-04 | Tibotec Pharmaceuticals | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
US20100168422A1 (en) | 2008-12-30 | 2010-07-01 | Weiping Chen | Methods and intermediates useful in the synthesis of hexahydrofuro [2,3-b]furan-3-ol |
WO2010086844A1 (en) | 2009-01-29 | 2010-08-05 | Mapi Pharma Hk Limited | Polymorphs of darunavir |
WO2011048604A2 (en) | 2009-09-17 | 2011-04-28 | Matrix Laboratories Limited | An improved process for the preparation of darunavir |
WO2011051978A2 (en) | 2009-10-30 | 2011-05-05 | Lupin Limited | A novel process for preparation of darunavir and darunavir ethanolate of fine particle size |
WO2011073993A1 (en) | 2009-12-16 | 2011-06-23 | Hetero Research Foundation | Polymorphs of darunavir |
WO2011083287A2 (en) | 2010-01-05 | 2011-07-14 | Cipla Limited | Darunavir polymorph and process for preparation thereof |
WO2011092687A1 (en) | 2010-01-28 | 2011-08-04 | Mapi Pharma Hk Limited | Process for the preparation of darunavir and darunavir intermediates |
WO2011141921A1 (en) | 2010-05-10 | 2011-11-17 | Hetero Research Foundation | Darunavir compositions |
-
2011
- 2011-01-24 MX MX2012008627A patent/MX2012008627A/en not_active Application Discontinuation
- 2011-01-24 AU AU2011210349A patent/AU2011210349A1/en not_active Abandoned
- 2011-01-24 CN CN2011800073810A patent/CN102725295A/en active Pending
- 2011-01-24 US US13/519,297 patent/US8829208B2/en active Active
- 2011-01-24 CA CA2784398A patent/CA2784398A1/en not_active Abandoned
- 2011-01-24 PL PL11736707T patent/PL2528923T3/en unknown
- 2011-01-24 JP JP2012550562A patent/JP2013518096A/en active Pending
- 2011-01-24 WO PCT/IL2011/000079 patent/WO2011092687A1/en active Application Filing
- 2011-01-24 ES ES11736707.8T patent/ES2516916T3/en active Active
- 2011-01-24 EP EP11736707.8A patent/EP2528923B1/en active Active
- 2011-01-24 BR BR112012018862A patent/BR112012018862A2/en not_active IP Right Cessation
Patent Citations (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415747A (en) | 1981-09-29 | 1983-11-15 | Union Carbide Corporation | Process for making ethylene glycol derivatives |
US6534493B1 (en) | 1992-08-25 | 2003-03-18 | G.D. Searle | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
WO1994004492A1 (en) | 1992-08-25 | 1994-03-03 | G.D. Searle & Co. | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6924286B1 (en) | 1992-08-25 | 2005-08-02 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US7115618B2 (en) | 1992-08-25 | 2006-10-03 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
EP0810209A2 (en) | 1992-08-25 | 1997-12-03 | G.D. Searle & Co. | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5744481A (en) | 1992-08-25 | 1998-04-28 | G.D. Searle & Co. | β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5786483A (en) | 1992-08-25 | 1998-07-28 | G. D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6455581B1 (en) | 1992-08-25 | 2002-09-24 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5843946A (en) | 1992-08-25 | 1998-12-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ES2123065T3 (en) | 1992-08-25 | 1999-01-01 | Searle & Co | HYDROXYETHYLAMINE-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. |
US6646010B2 (en) | 1992-08-25 | 2003-11-11 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6472407B1 (en) | 1992-08-25 | 2002-10-29 | G.D. Searle & Co. | α and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US7320983B2 (en) | 1992-08-25 | 2008-01-22 | G.D. Searle Llc | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6248775B1 (en) | 1992-08-25 | 2001-06-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6046190A (en) | 1992-08-25 | 2000-04-04 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
US6060476A (en) | 1992-08-25 | 2000-05-09 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
FI119427B (en) | 1992-08-25 | 2008-11-14 | Searle & Co | Process for Preparation of Hydroxyethylaminosulfonamides Useful as Retrovirus Protease Inhibitors |
US6172082B1 (en) | 1992-08-25 | 2001-01-09 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6846954B2 (en) | 1992-08-25 | 2005-01-25 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6500832B1 (en) | 1992-08-25 | 2002-12-31 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DE69332002T2 (en) | 1992-08-25 | 2002-12-19 | Monsanto Co | Hydroxyethylaminosulfonamides can be used as inhibitors of retroviral proteases |
US6335460B1 (en) | 1992-08-25 | 2002-01-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
US7531538B2 (en) | 1992-08-25 | 2009-05-12 | G.D. Searle Llc | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ES2177868T3 (en) | 1992-08-25 | 2002-12-16 | Searle & Co | HYDROXYETHYLAMINOSULPHONAMIDS OF ALPHA- AND BETA-AMINO ACIDS AS INHIBITORS OF RETROVIRIC PROTEASES. |
US6417387B1 (en) | 1992-08-25 | 2002-07-09 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5830897A (en) | 1992-08-27 | 1998-11-03 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ES2127938T3 (en) | 1993-08-24 | 1999-05-01 | Searle & Co | HYDROXYETHYLAMINE SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. |
WO1995006030A1 (en) | 1993-08-24 | 1995-03-02 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
EP0715618A1 (en) | 1993-08-24 | 1996-06-12 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
EP0754669A1 (en) | 1995-02-03 | 1997-01-22 | Kaneka Corporation | Processes for producing alpha-halo ketones, alpha-halohydrins and epoxides |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6703403B2 (en) | 1995-06-29 | 2004-03-09 | Abbott Laboratories | Method for improving pharmacokinetics |
JPH09124629A (en) | 1995-10-26 | 1997-05-13 | Kissei Pharmaceut Co Ltd | Production of tetrahydrofuryl carbamate derivative |
US6613743B2 (en) | 1998-06-19 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
WO1999067254A2 (en) | 1998-06-23 | 1999-12-29 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Multi-drug resistant retroviral protease inhibitors and use thereof |
WO1999067417A2 (en) | 1998-06-23 | 1999-12-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fitness assay and associated methods |
US7470506B1 (en) | 1998-06-23 | 2008-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Fitness assay and associated methods |
EP1029856A1 (en) | 1998-08-25 | 2000-08-23 | Kaneka Corporation | Process for the preparation of (2r, 3s)-3-amino-1,2-oxirane |
EP1661893A2 (en) | 1999-01-29 | 2006-05-31 | Kaneka Corporation | Process for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives |
EP1067125A1 (en) | 1999-01-29 | 2001-01-10 | Kaneka Corporation | PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES |
EP1081133A1 (en) | 1999-08-31 | 2001-03-07 | Ajinomoto Co., Inc. | Method for producing N-carbamate-protected beta-aminoepoxide and beta-aminoalcohol |
US6852887B2 (en) | 1999-12-23 | 2005-02-08 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-P-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
US20020026079A1 (en) | 2000-08-16 | 2002-02-28 | David Kronenthal | Process for the preparation of alpha' chloroketones |
EP1215209A1 (en) | 2000-12-12 | 2002-06-19 | Ajinomoto Co., Inc. | Method for the production of a crystalline epoxide |
WO2003022853A1 (en) | 2001-09-10 | 2003-03-20 | Tibotec Pharmaceuticals Ltd. | Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol |
WO2003024974A2 (en) | 2001-09-20 | 2003-03-27 | Smithkline Beecham Corporation | Process for preparing protease inhibitor intermediates |
US20050089164A1 (en) | 2001-12-30 | 2005-04-28 | Lang Juergen K. | System and method for the production and distribution of copy-protected and use-protected electronic audio and visual media and the data contents thereof |
WO2003060905A1 (en) | 2001-12-30 | 2003-07-24 | Lang Juergen K | System and method for the production and distribution of copy-protected and use-protected electronic audio and visual media and the data contents thereof |
US20050250845A1 (en) | 2002-05-16 | 2005-11-10 | Tibotec Parmaceuticeals | Pseudopolymorphic forms of a hiv protease inhibitor |
US7700645B2 (en) | 2002-05-16 | 2010-04-20 | Tibotec Pharmaceuticals Ltd. | Pseudopolymorphic forms of a HIV protease inhibitor |
CN1668623A (en) | 2002-05-16 | 2005-09-14 | 泰博特克药品有限公司 | Pseudopolymorphic forms of a HIV protease inhibitor |
WO2003106461A2 (en) | 2002-05-16 | 2003-12-24 | Tibotec Pharmaceuticals Ltd | Pseudopolymorphic forms of a hiv protease inhibitor |
CA2485834A1 (en) | 2002-05-16 | 2003-12-24 | Tibotec Pharmaceuticals Ltd. | Pseudopolymorphic forms of a hiv protease inhibitor |
WO2004016619A1 (en) | 2002-08-14 | 2004-02-26 | Tibotec Pharmaceuticals Ltd. | Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
US6919465B2 (en) | 2002-10-09 | 2005-07-19 | The Board Of Trustees Of The University Of Illinois | Method of preparing (3R, 3aS, 6aR)-3-hydroxyhexahydrofuro[2,3,-b] furan and related compounds |
US20040127727A1 (en) | 2002-10-09 | 2004-07-01 | Ghosh Arun K. | Method of preparing (3R, 3aS, 6aR) -3-hydroxyhexahydrofuro [2,3,-b] furan and related compounds |
WO2004033462A2 (en) | 2002-10-09 | 2004-04-22 | The Board Of Trustees Of The University Of Illinois | METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS |
US20050256322A1 (en) | 2002-12-27 | 2005-11-17 | Sumitomo Chemical Company, Limited | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof |
US20040162340A1 (en) | 2002-12-27 | 2004-08-19 | Sumika Fine Chemicals Co., Ltd. | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof |
WO2004094465A2 (en) | 2003-04-23 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign | Synthetic molecules that mimic chemokines |
WO2005000249A2 (en) | 2003-06-27 | 2005-01-06 | Smithkline Beecham Corporation | Preparation of chemical compounds |
US20060148865A1 (en) | 2003-06-27 | 2006-07-06 | Martin Michael T | Preparation of chemical compounds |
WO2005063770A1 (en) | 2003-12-23 | 2005-07-14 | Tibotec Pharmaceuticals Ltd. | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
US20070060642A1 (en) | 2003-12-23 | 2007-03-15 | Goyvaerts Nicolaas Martha Feli | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
WO2005087728A1 (en) | 2004-03-11 | 2005-09-22 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
WO2005095410A1 (en) | 2004-03-31 | 2005-10-13 | Tibotec Pharmaceuticals Ltd. | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL |
WO2005110428A2 (en) | 2004-05-07 | 2005-11-24 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
US20060135562A1 (en) | 2004-11-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and darunavir |
US20060135563A1 (en) | 2004-12-01 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and SCH-417690 |
WO2006108879A2 (en) | 2005-04-15 | 2006-10-19 | Tibotec Pharmaceuticals Ltd. | Use of a sulfonamide compound for improving the pharmacokinetics of a drug |
WO2006132390A1 (en) | 2005-06-06 | 2006-12-14 | Sumitomo Chemical Company, Limited | Method for producing hexahydrofurofuranol derivative |
EP1889826A1 (en) | 2005-06-06 | 2008-02-20 | Sumitomo Chemical Company, Limited | Method for producing hexahydrofurofuranol derivative |
WO2007060253A1 (en) | 2005-11-28 | 2007-05-31 | Tibotec Pharmaceuticals Ltd. | Substituted aminophenylsulfonamide compounds as hiv protease inhibitor |
WO2007126812A2 (en) | 2006-03-29 | 2007-11-08 | Gilead Sciences, Inc. | Process for preparation of hiv protease inhibitors |
WO2008016522A2 (en) | 2006-07-24 | 2008-02-07 | Gilead Sciences, Inc. | Hiv reverse transcriptase inhibitors |
WO2008034598A1 (en) | 2006-09-19 | 2008-03-27 | Dsm Ip Assets B.V. | Method for the synthesis of hexahydrofuro (2, 3-b) furan-3-ol compounds |
WO2008055970A2 (en) | 2006-11-09 | 2008-05-15 | Tibotec Pharmaceuticals Ltd. | Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol |
WO2008132154A1 (en) | 2007-04-27 | 2008-11-06 | Tibotec Pharmaceuticals Ltd. | Methods for the preparation of n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives |
WO2009000853A2 (en) | 2007-06-25 | 2008-12-31 | Tibotec Pharmaceuticals Ltd. | Combination formulations comprising darunavir and etravirine |
WO2009005674A2 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
WO2009030733A1 (en) | 2007-09-04 | 2009-03-12 | Dsm Ip Assets B.V. | Method for the synthesis of 4-alkoxy-, 4-hydroxy- and 4-aryloxy-substituted tetrahydro-furo[3,4-b]furan-2(3h)-one compounds |
US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
WO2009081174A2 (en) | 2007-12-24 | 2009-07-02 | Cipla Limited | Anti - retroviral combination |
WO2010002998A1 (en) | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
WO2010023322A1 (en) | 2008-09-01 | 2010-03-04 | Tibotec Pharmaceuticals | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
US20100168422A1 (en) | 2008-12-30 | 2010-07-01 | Weiping Chen | Methods and intermediates useful in the synthesis of hexahydrofuro [2,3-b]furan-3-ol |
US20120035142A1 (en) | 2009-01-29 | 2012-02-09 | Mapi Pharma Limited | Polymorphs of darunavir |
WO2010086844A1 (en) | 2009-01-29 | 2010-08-05 | Mapi Pharma Hk Limited | Polymorphs of darunavir |
WO2011048604A2 (en) | 2009-09-17 | 2011-04-28 | Matrix Laboratories Limited | An improved process for the preparation of darunavir |
WO2011051978A2 (en) | 2009-10-30 | 2011-05-05 | Lupin Limited | A novel process for preparation of darunavir and darunavir ethanolate of fine particle size |
WO2011073993A1 (en) | 2009-12-16 | 2011-06-23 | Hetero Research Foundation | Polymorphs of darunavir |
WO2011083287A2 (en) | 2010-01-05 | 2011-07-14 | Cipla Limited | Darunavir polymorph and process for preparation thereof |
WO2011092687A1 (en) | 2010-01-28 | 2011-08-04 | Mapi Pharma Hk Limited | Process for the preparation of darunavir and darunavir intermediates |
WO2011141921A1 (en) | 2010-05-10 | 2011-11-17 | Hetero Research Foundation | Darunavir compositions |
Non-Patent Citations (18)
Title |
---|
Beaulieu, Pierre L et al., (1995) Large scale preparation of (2S,3S)-N-Boc-3-amino-1,2-epoxy-4-phenylbutane: A key building block for HIV-protease inhibitors Tetrahedron Letters, 1995, 36(19):3317-3320. |
Brittain H.G. (1999) Polymorphism in Pharmaceutical Solids. CRC Press, New York City, pp. 184-226. |
Bull, Steven D. et al.,(1998) Chiral relay auxiliaries. Pure & Appl. Chem. 70(8):1501-1506. |
Cohen, Noal et al., (1983) Enantiospecific syntheses of leukotrienes C4, D4, and E4, and [14,15-3H2]leukotriene E4 dimethyl ester. J. Am. Chem. Soc. 105(11):3661-3672. |
Contreras, Jordi and Jones, J. Idris (1980) Synthesis of Poly(p-Benzenesulphonamide) Part I. Preparation of Sulphanilic Acid Derivatives for Use as Intermediates. British Polymer Journal 12(4):192-198. |
Ghosh, Arun K. et al., (1998) Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg Med Chem Lett 8(6):687-690. |
Ghosh, Arun K. et al., (2004) Stereoselective Photochemical 1,3-Dioxolane Addition to 5-Alkoxymethy1-2(5H)-furanone: Synthesis of Bis-tetrahydrofuranyl Ligand for HIV Protease Inhibitor UIC-94017 (TMC-114) J. Org Chem. 69 (2004) 7822-7829. |
Gioeli, Carlo and Chattopadhyaya, Jyoti B. (1982) The fluoren-9-ylmethoxycarbonyl group for the protection of hydroxy-groups; its application in the synthesis of an octathymidylic acid fragment. J Chem Soc, Chem commun 1982 (12):672-674. |
Griffith, William P. et al, (1987) Preparation and use of tetra-n-butylammonium per-ruthenate (TBAP reagent) and tetra-n-propylammonium per-ruthenate (TPAP reagent) as new catalytic oxidants for alcohols. J. Chem. Soc. Chem Commun. 1987(21):1625-1627. |
Guanti, Giuseppe et al., (2002) O-Protecting groups as long-range stereocontrolling elements in the addition of acetylides to 4-substituted quinolines. Tetrahedron: Asymmetry 13(24):2703-2726. |
Honda, Yutaka et al., (2004) New approaches to the industrial synthesis of HIV protease inhibitors. Org. Biomol. Chem. 2(14):2061-2070. |
ISR of PCT/IL2010/000533 Jun. 3, 2011. |
ISR of PCT/IL2011/000079 Jun. 13, 2011. |
Li, Hui-Zhang et al., (2003) A study on the sulfonation of aromatic amines with sulfuric acid under microwave irradiation. Journal of Chemical Research, Synopses 2003(8):493-494. |
Miller, John F. et al., (2004) Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorg Med Chem Lett 14(4):959-963. |
Steffan, Robert J. et al., (2002) Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines. Bioorg Med Chem Lett 12(20):2963-2967. |
Surleraux, Dominic L. N. G. et al., (2005) Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 48(6):1813-1822. |
Wenger, Ronald Maurice (1985) Synthesis of Cyclosporine and Analogues: Structural Requirements for Immunosuppressive Activity. Angew. Chim. Int. Ed. Eng. 24(2):77-85. |
Also Published As
Publication number | Publication date |
---|---|
CN102725295A (en) | 2012-10-10 |
ES2516916T3 (en) | 2014-10-31 |
EP2528923A4 (en) | 2013-06-19 |
PL2528923T3 (en) | 2015-01-30 |
EP2528923A1 (en) | 2012-12-05 |
AU2011210349A1 (en) | 2012-07-05 |
WO2011092687A1 (en) | 2011-08-04 |
BR112012018862A2 (en) | 2015-10-13 |
JP2013518096A (en) | 2013-05-20 |
EP2528923B1 (en) | 2014-07-30 |
MX2012008627A (en) | 2012-09-21 |
CA2784398A1 (en) | 2011-08-04 |
US20120296101A1 (en) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8829208B2 (en) | Process for the preparation of darunavir and darunavir intermediates | |
JP5491862B2 (en) | Process for producing hexahydrofuro [2,3-b] furan-3-ol | |
US7595408B2 (en) | Methods for the preparation of (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol | |
US9216990B2 (en) | Crystalline Darunavir | |
US20100217000A1 (en) | Process for the Preparation of Thiazolopyrimidines | |
US8076513B2 (en) | Methods for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives | |
DK2643326T3 (en) | A process for the preparation of (3R, 3aS, 6aR) -hexahydrofuro [2,3-b] furan-3-ol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MAPI PHARMA LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MIZHIRITSKII, MICHAEL;MAROM, EHUD;SIGNING DATES FROM 20120531 TO 20120603;REEL/FRAME:028447/0641 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |